August 6, 2026Open Access
Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy
Key Result
Intensive systolic blood pressure lowering reduced the incidence of malignant LVH over two years compared to standard therapy (1.1% vs 2.5%; OR 0.44; 95% CI 0.30-0.63).
Key Points
- This study aims to evaluate the effects of intensive systolic blood pressure control on preventing malignant left ventricular hypertrophy and its associated risks.
- 8,820 participants from the Systolic Blood Pressure Intervention Trial (SPRINT) were assessed for left ventricular hypertrophy using 12-lead ECG and cardiac biomarkers.
- Participants were categorized based on the presence of LVH and biomarker levels, then randomly assigned to intensive or standard blood pressure control.
- The study evaluated rates of acute decompensated heart failure and death over four years and monitored the incidence of malignant LVH over two years.
- Intensive blood pressure lowering produced a 4.4% absolute risk reduction in acute decompensated heart failure events and death for those with malignant LVH (n=449).
- For participants without LVH, the absolute risk reduction was 1.2% (n=4361).
- The incidence of malignant LVH decreased from 2.5% to 1.1% with intensive blood pressure management, with an odds ratio of 0.44 (95% CI: 0.30, 0.63).
Study Design
Type
RCT (n=8,820)
Randomization
Randomized
Structured PICO
Does intensive systolic blood pressure lowering reduce acute decompensated heart failure events, death, and the incidence of malignant LVH in patients with or without baseline malignant LVH?
P
Population
8,820 participants in the Systolic Blood Pressure Intervention Trial (SPRINT) evaluated for the impact of intensive systolic blood pressure control over up to four years.
I
Intervention
Intensive systolic blood pressure (SBP) lowering
C
Comparator
Standard systolic blood pressure (SBP) lowering
O
Outcome
Composite of acute decompensated heart failure (ADHF) events and death over four years; incidence and regression of malignant LVH over two yearscomposite
Intensive blood pressure lowering significantly reduces the incidence of malignant left ventricular hypertrophy and may provide substantial absolute risk reductions in heart failure events and death for high-risk patients.
Main Result
Odds Ratio: 0.44 (95% CI 0.3–0.63)
Absolute Event Rate: 1.1% vs 2.5%
Abstract
Background: Left ventricular hypertrophy (LVH) combined with elevations in cardiac biomarkers reflecting myocardial injury and neurohormonal stress (malignant LVH) is associated with a high risk for heart failure and death. Objectives: The aim of this study was to determine the impact of intensive systolic blood pressure (SBP) control on the prevention of malignant LVH and its consequences. Methods: 8,820 participants in the Systolic Blood Pressure Intervention Trial (SPRINT) were classified into groups based on the presence or absence of LVH assessed by 12-lead ECG, and elevations in biomarker levels (high-sensitivity cardiac troponin T ≥14 ng/L or N-terminal pro-B-type natriuretic peptide ≥125 pg/mL) at baseline. The effects of intensive versus standard SBP lowering on rates of acute decompensated heart failure (ADHF) events and death and on the incidence and regression of malignant LVH were determined. Results: Randomization to intensive SBP lowering led to similar relative reductions in ADHF events and death across the combined LVH/biomarker groups (P for interaction =0.68). The absolute risk reduction over four years in ADHF events and death was 4.4% (95% CI: −5.2%, 13.9%) among participants with baseline malignant LVH (n=449) and 1.2% (95% CI: 0.0%, 2.5%) for those without LVH and non-elevated biomarkers (n=4361). Intensive SBP lowering also reduced the incidence of malignant LVH over two years (2.5% vs. 1.1%, odds ratio: 0.44, 95% CI: 0.30, 0.63). Conclusions: Intensive SBP lowering prevented malignant LVH and may provide substantial absolute risk reduction in the composite of ADHF events and death among SPRINT participants with baseline malignant LVH.
Expert Takes1 quote
“Previous studies have shown that malignant LVH is associated with a unique natural history characterized by a high risk for heart failure and death. However, until now, we had no proven therapies for its treatment. Our data suggest for the first time that this risk is modifiable through intensive lowering of blood pressure to less than 120 mmHg.”
Jarett Berry, Chair of Medicine, UT Tyler School of MedicineUniversity of Texas at Tyler School of Medicineauto_pipelineView source
Cite This Study
Ascher et al. (Sat,) conducted a rct in Hypertension and left ventricular hypertrophy (n=8,820). Intensive systolic blood pressure lowering vs. Standard systolic blood pressure lowering was evaluated on Incidence of malignant LVH over two years (OR 0.44, 95% CI 0.30, 0.63). Intensive systolic blood pressure lowering reduced the incidence of malignant LVH over two years compared to standard therapy (1.1% vs 2.5%; OR 0.44; 95% CI 0.30-0.63).